Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer.
Daniel Fernandez-GarciaGeorgios NteliopoulosRobert K HastingsAmelia RushtonKaren PageRebecca C AllsoppBana AmbasagerKelly GleasonDavid S GutterySimak AliRaoul Charles CoombesJacqueline A ShawPublished in: British journal of cancer (2022)
This combined analysis of CTCs and ctDNA may offer a new approach for monitoring of disease progression and to direct therapy in patients with advanced MBC, at a time when they are coming towards the end of other treatment options.